For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
"Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline Insight, 2019" report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across "Angiotensin Converting Enzyme (ACE) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:
- Inactive: Discontinued and/or Dormant
Descriptive coverage of pipeline development activities for "Angiotensin Converting Enzyme (ACE) Inhibitor - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Pipeline Therapeutics assessment of products for "Angiotensin Converting Enzyme (ACE) Inhibitor
The report assesses the active Angiotensin Converting Enzyme (ACE) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route.
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Scope of the report
- Provides a snapshot of the therapeutics pipeline activity for "Angiotensin Converting Enzyme (ACE) Inhibitor
- Features the Angiotensin Converting Enzyme (ACE) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages
- Offers detailed therapeutic product profiles of Angiotensin Converting Enzyme (ACE) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across "Angiotensin Converting Enzyme (ACE) Inhibitor
Reasons to Buy
- Establish a comprehensive understanding of the current pipeline scenario across Angiotensin Converting Enzyme (ACE) Inhibitor to formulate effective R&D strategies
- Assess challenges and opportunities that influence Angiotensin Converting Enzyme (ACE) Inhibitor research & development (R&D)
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify and understand the sought after therapy areas and indications for "Angiotensin Converting Enzyme (ACE) Inhibitor
- Identify the product attributes and use it for target finding, drug repurposing, and precision medicine
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Angiotensin Converting Enzyme (ACE) Inhibitor to enhance and expand business potential and scope
- Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
- Our extensive domain knowledge on therapy areas supports the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs